Aeglea Biotherapeutics, Inc. (AGLE)

NASDAQ: AGLE · IEX Real-Time Price · USD
4.36 -0.11 (-2.46%)
Jan 25, 2022 4:00 PM EST - Market closed
Market Cap215.04M
Revenue (ttm)15.10M
Net Income (ttm)-68.07M
Shares Out49.32M
EPS (ttm)-1.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume76,001
Open4.47
Previous Close4.47
Day's Range4.28 - 4.51
52-Week Range3.47 - 8.79
Beta1.44
AnalystsBuy
Price Target13.63 (+212.6%)
Earnings Daten/a

About AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeli...

IndustryBiotechnology
IPO DateApr 7, 2016
Employees90
Stock ExchangeNASDAQ
Ticker SymbolAGLE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AGLE stock is "Buy." The 12-month stock price forecast is 13.63, which is an increase of 212.61% from the latest price.

Price Target
$13.63
(212.61% upside)
Analyst Consensus: Buy

News

Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency

AUSTIN, Texas, Jan. 25, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...

16 hours ago - PRNewsWire

Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022

AUSTIN, Texas , Jan. 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...

2 weeks ago - PRNewsWire

3 Biotech Stocks That Sank: Are Any a Bad-News Buy?

At least one of the three could be in store for better news in the future.

Other symbols:BOLTRETA
1 month ago - The Motley Fool

Why Aeglea BioTherapeutics Stock Is Way Down Today

MIxed phase 3 clinical trial results are making investors nervous.

1 month ago - The Motley Fool

Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with ...

AUSTIN, Texas, Dec. 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

1 month ago - PRNewsWire

Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with A...

AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

1 month ago - PRNewsWire

Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors

AUSTIN, Texas, Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

2 months ago - PRNewsWire

Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Tops Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of -6.90% and 1.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

2 months ago - PRNewsWire

Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE S...

AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...

2 months ago - PRNewsWire

Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021

AUSTIN, Texas, Sept. 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peopl...

4 months ago - PRNewsWire

Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Tops Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of 47.37% and 112.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

5 months ago - PRNewsWire

Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel

AUSTIN, Texas, July 15, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

6 months ago - PRNewsWire

Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzi...

AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

6 months ago - PRNewsWire

Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer

AUSTIN, Texas, July 8, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...

6 months ago - PRNewsWire

Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Trea...

AUSTIN, Texas, June 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

7 months ago - PRNewsWire

Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors

AUSTIN, Texas, June 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

7 months ago - PRNewsWire

Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights

AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

8 months ago - PRNewsWire

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of...

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people w...

8 months ago - PRNewsWire

Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginas...

AUSTIN, Texas, May 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...

8 months ago - PRNewsWire

Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021

AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people...

9 months ago - PRNewsWire

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Argi...

AUSTIN, Texas and STOCKHOLM, March 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

10 months ago - PRNewsWire

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

AUSTIN, Texas, March 18, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

10 months ago - PRNewsWire

Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors

AUSTIN, Texas, Feb. 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

11 months ago - PRNewsWire